GNH USA

Europe — EMA

Irinotecan Accord

GNH USA supplies Irinotecan Accord (Irinotecan), a Topoisomerase I inhibitor for metastatic colorectal cancer. Request a quote for supply with pricing.

Irinotecan Hydrochloride Trihydrate

Request sourcing

1
Pack/s

What is Irinotecan Hydrochloride Trihydrate?

Irinotecan, the active ingredient in Irinotecan Accord, is a Topoisomerase I inhibitor presented as an injectable solution for intravenous administration. It is used in the treatment of metastatic colorectal cancer, targeting adult patients whose disease has progressed despite prior therapy.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, and pharmacies worldwide under strict quality standards. The company ensures compliance with EU regulations and supports cold‑chain logistics where required through its global distribution network.

What is Irinotecan Hydrochloride Trihydrate used for?

Irinotecan is indicated for the treatment of metastatic colorectal cancer, a solid tumor that depends on topoisomerase I activity for DNA replication.

Metastatic colorectal cancer: Improves disease control and overall survival when used in combination chemotherapy regimens.

What are the side effects of Irinotecan Hydrochloride Trihydrate?

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia - Diarrhea - Nausea - Fatigue

Serious or Rare Side Effects: - Febrile neutropenia - Severe colitis or watery diarrhea - Allergic reactions, including anaphylaxis

What precautions apply to Irinotecan Hydrochloride Trihydrate?

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood counts: Perform regular CBC to detect neutropenia Assess liver function: Check transaminases before and during treatment Hydration: Maintain adequate fluid intake to reduce risk of severe diarrhea Avoid concurrent myelosuppressive agents: Minimize additive bone‑marrow toxicity Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake

What does Irinotecan Hydrochloride Trihydrate interact with?

Irinotecan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive chemotherapy: Increases risk of severe neutropenia - Strong CYP3A4 inhibitors (e.g., ketoconazole): Elevate irinotecan plasma levels - UGT1A1*28 polymorphism carriers: Higher risk of toxicity, consider dose adjustment

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): May reduce therapeutic effect - Anticholinergic agents: May worsen constipation

Frequently asked questions

What is Irinotecan Accord used for?+
Irinotecan Accord is used as a chemotherapy agent for adult patients with metastatic colorectal cancer. It is administered as part of combination regimens to help control tumor growth and extend survival when the disease has progressed after prior treatments.
How does Irinotecan work?+
Irinotecan is a prodrug that is converted inside cells to the active metabolite SN‑38. SN‑38 inhibits the enzyme topoisomerase I, which is essential for DNA replication. By preventing DNA strand religation, the drug causes DNA damage that leads to cancer cell death.
What determines the dose of Irinotecan Accord?+
The prescribed dose of Irinotecan Accord is determined by the treating oncologist based on factors such as the patient’s body surface area, overall health, liver function, and prior chemotherapy exposure. No fixed dosing schedule is provided here; the prescriber tailors the regimen to each individual.
Is Irinotecan safe during pregnancy or breastfeeding?+
Safety data for Irinotecan in pregnancy and lactation are limited. Because the drug can cross the placenta and may be excreted in breast milk, it is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is essential.
How do I order Irinotecan Accord from GNH USA?+
To order Irinotecan Accord, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.
How does Irinotecan compare with other chemotherapy agents?+
Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as topotecan (another topoisomerase I inhibitor) and from antimetabolites like 5‑fluorouracil. Compared with some alternatives, Irinotecan often shows activity in tumors resistant to 5‑FU, but it carries a distinct toxicity profile, notably higher rates of diarrhea and neutropenia.
How should Irinotecan Accord be stored and handled?+
Irinotecan Accord should be stored refrigerated at 2 °C to 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product must be transported, maintain the cold‑chain throughout the journey.
How is Irinotecan administered?+
Irinotecan Accord is given by intravenous infusion, typically over 30 to 90 minutes depending on the regimen. The infusion is performed in a clinical setting under the supervision of qualified healthcare professionals, who monitor the patient for immediate reactions and adjust the infusion rate as needed.
What are the most serious risks associated with Irinotecan?+
The most serious risks include severe neutropenia that can lead to infection, febrile neutropenia, and life‑threatening diarrhea (colitis). Additionally, rare but severe allergic reactions such as anaphylaxis may occur. Patients should be closely monitored for signs of infection, fever, or persistent gastrointestinal symptoms.
Who should not receive Irinotecan Accord?+
Irinotecan should be avoided in patients with known hypersensitivity to the drug or its excipients, those with severe bone‑marrow suppression, uncontrolled infections, or significant liver dysfunction that cannot be managed. Caution is also advised for individuals with known UGT1A1*28 polymorphism due to increased toxicity risk.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Irinotecan Hydrochloride Trihydrate
Route
Intravenous Use
Manufacturer
Accord Healthcare France Sas
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU